Perlegen Sciences, Inc. has expanded its relationship with GlaxoSmithKline with an agreement that enables multiple genetics related studies to be conducted over a period of time. Two previous whole genome association studies were announced, one in October 2004, and another, Perlegen’s first pharmaceutical collaboration, in September 2002. Terms of the deal were not disclosed.

Perlegen Sciences, Inc. analyzes millions of genetic variations in DNA samples obtained from clinical trial participants. This information is used to explain and predict the efficacy and adverse effect profiles of prescription drugs. Perlegen also applies this expertise to discovering genetic variants associated with disease for potential new therapeutics and diagnostics.